IL2 and melanoma: One FDA-approved cytokine-based therapy, high-dose IL-2 therapy (HD IL-2), yields a 15–20% objective response rate in metastatic renal cell carcinoma and melanoma3,4, and a further improved clinical response was observed when HD IL-2 was combined with a melanoma peptide vaccine5,6.